Table 1.
Study Population: Demographics and General Description
| Familial Cohort | Sporadic Cohort | Combined | |
|---|---|---|---|
| Total individuals, n, % | 1231 (71.4) | 494 (28.6) | 1725 (100) |
| Females, n, % | 668 (54.3) | 250 (50.6) | 918 (53.2) |
| Current age, median (range [IQR]) | 46.2 (2–97 [32–62]) | 35 (3–77 [26–42]) | 42.6 (2–97 [29–56]) |
| Clinical status, n, % | |||
| Affected | 502 (40.8) | 404 (81.8) | 906 (52.5) |
| Unaffected | 729 (59.2) | 90 (18.2) | 819 (47.5) |
| Affected males, n, % | 219 (43.6) | 203 (50.2) | 422 (46.6) |
| Affected females, n, % | 283 (56.4) | 201 (49.8) | 484 (53.4) |
| Diagnoses, n, % | |||
| Acromegaly | 170 (33.9) | 203 (50.2) | 373 (41.2) |
| Acromegaly/prolactinoma | 17 (3.4) | 12 (3) | 29 (3.2) |
| Cushing's disease | 24 (4.8) | 21 (5.2) | 45 (5) |
| FSHoma | 2 (0.4) | 1 (0.2) | 3 (0.3) |
| Gigantism | 44 (8.8) | 65 (16.1) | 109 (12) |
| Gigantism/prolactinoma | 1 (0.2) | 10 (2.5) | 11 (1.2) |
| Mild acromegaly | 2 (0.4) | — | 2 (0.2) |
| NFPA | 91 (18.1) | 21 (5.2) | 112 (12.4) |
| Pituitary tumor | 17 (3.4) | 2 (0.5) | 19 (2.1) |
| Prolactinoma | 134 (26.7) | 67 (16.6) | 201 (22.2) |
| TSHoma | — | 2 (0.5) | 2 (0.2) |
| GH excess patients, n, % | 234 (46.6) | 290 (71.8) | 524 (57.8) |
Abbreviations: FSHoma, FSH secreting adenoma. TSHoma, thyrotropinoma.
Dash indicates no patients in this category.